###### Strengths and limitations of this study

-   Prospective multicentric study.

-   Description of factors associated with long sick leave.

-   Multimodal analysis including evaluation of costs of sick leave.

-   Few qualitative information.

Introduction {#s1}
============

Improvements in early detection and treatment have resulted in an increasing number of breast cancer (BC) survivors.[@R1] Treatments mostly focus on curing the disease and preventing metastatic relapse. About one-third of women diagnosed with BC are under the age of 55 with a 10-year survival close to 80%.[@R2] Many patients therefore recover and resume their activities of daily living during or after treatment. Return to work (RTW) is an event at the end of sick leave, consisting in resuming professional activity. RTW after BC is still a new but important aspect of survivorship research, not only from a societal point of view, as it provides financial resources for rehabilitation of cancer survivors and contributes to psychosocial well-being, including physical and mental health.[@R3] Some BC cancer survivors experience reduced work ability.[@R4] Difficulties at work or unemployment differ according to the type of BC treatment. Cancer treatment varies according to the stage of the disease and can include surgery, chemotherapy, radiotherapy and hormone therapy. For many patients with cancer, RTW helps them to recover from treatment and also constitutes a positive step towards the future. The identification of factors that maintain patients at work during ~~and after~~ BC treatment could help healthcare professionals to more accurately identify patients at risk of RTW-related difficulties in order to provide them with adapted support during BC management. The aim of this prospective study was to describe work during and after BC management and identify factors associated with either cessation or maintenance at work.

Materials and methods {#s2}
=====================

OPTISOINS01 was an observational, prospective, multicentre study conducted from December 2014 to March 2016 among patients with BC from a regional health territory. The primary objective of the Optisoins01 study was to identify the main care pathway after 1 year of early BC and to evaluate costs from various perspectives. RTW evaluation was one of the secondary objectives of the study. The Optisoins01 study design has been previously described.[@R9] Eight non-profit hospitals participated in the study: three teaching hospitals, four general hospitals and one comprehensive cancer centre. Inclusion criteria were: women aged ≥18 years with previously untreated, first, histologically confirmed, operable BC. Exclusion criteria were: metastatic, locally advanced or inflammatory BC and previous history of BC.

After BC diagnosis, a work and cancer information booklet had to be given to all working patients. Our Institute has designed an information booklet in collaboration with occupational physicians and the Paris Regional Health Insurance (Caisse Régionale d'Assurance Maladie d'Île-de-France). This document includes the testimonies from employees, advice and practical information to help patients anticipate difficulties and find support: possibility of part-time work, career development plan, roles of occupational physicians and general practitioners. The booklet is freely available online with the support of the 'ARC' Foundation.[@R10]

After inclusion, all patients were given a logbook in which to record, throughout the year, sociodemographic data (age, marital status, type of occupation, personal income and so on), out-of-pocket health expenses and a 1-year occupational questionnaire for employed women including dates of work and absence from work during treatments, job adjustments, on-shift status and the perceived quality of reintegration with standardised self-questionnaire (income change, difficulties at work with co-workers and/or with superiors and so on). Patients were asked to fill in the questionnaire prospectively during the all study period. During the second half of the year, clinical research assistants made two phone calls to remind patients to fill in the logbook. Questionnaires were collected at the end of the study. Types of occupations were classified according to the French *Institut National de la Statistique et des Etudes Economiques (INSEE)* classification.

Two groups of patients were compared in order to determine the factors associated with sick leave duration: longer sick leave (longer or equal to the median duration) and shorter sick leave (shorter than the median duration). Fisher's exact test or Student's t-test were used to analyse these factors. These tests were two sided with a 0.05 level of significance. Multivariate analysis was performed using a logistic regression model. We considered adjusted p value for multiple comparisons. Sick leave over a 1-year period was described according to whether or not the patients were treated by chemotherapy. Differences in the areas under the curves of the two populations were compared with 1000 permutations of random allocation of chemotherapy. The same analysis was performed according to whether or not the patients had received the work information booklet. Differences were considered significant for p\<0.05. All statistical analyses were performed with R software.[@R11]

The cost of sick leave for National Health Insurance was calculated on the basis of the monthly income declared by the patients, the duration of sick leave and the national sick leave allowance scale.

This study was registered with ClinicalTrials.gov (Identifier: NCT02813317) and was approved by the French National ethics committee (CCTIRS Authorisation No. 14.602 and CNIL DR-2014--167) covering research at all participating hospitals.

Patient and public Involvement: A sample of patients participated in the questionnaire development concerning work activity before implementation of the study. Patients were involved in the study by actively completing the questionnaires during 1 year. A results-report will be sent to the study participants.

Results {#s3}
=======

Six hundred and four patients with a median age of 58 years (range: 24--98) were included in the Optisoins01 study, including 297 patients (48.2%) who were working at the time of BC diagnosis. The present study focused on these 297 patients.

Detailed patient characteristics and cancer characteristics are presented in [table 1](#T1){ref-type="table"}. The median age of the women was 50 (range: 27--77) years, 54 women (18.2%) were single, 153 (51.5%) were married, 39 (13.1%) were divorced and 3 (1.0%) were widows. Two hundred and sixty-one patients (87.9%) had invasive BC and 35 (11.8%) had in situ BC. Seventy-five women (25.3%) presented with axillary lymph node involvement.

###### 

Patient and cancer characteristics and breast cancer treatments (n=297)

                                      n or Median   \% or Range
  ----------------------------------- ------------- -------------
  **Patient characteristics**                       
  Age (years)                         50            27--77
  Marital status                                    
   Single                             54            18.2
   Married                            153           51.5
   Divorced                           39            13.1
   Widow                              3             1
   NA                                 48            16.2
  **Breast cancer characteristics**                 
  Modes of diagnosis                                
   Organised screening                60            20.2
   Individual screening               114           38.4
   Clinical signs                     123           41.4
  Type of cancer                                    
   Invasive                           261           87.9
   In situ                            35            11.8
   NA                                 1             0.3
  Lymph node involvement                            
    Yes                               75            25.3
    No                                222           74.7
  **Surgery**                                       
  Breast surgery                                    
   Conservative                       220           74.1
   Radical                            77            25.9
  Lymph node surgery                                
   Sentinel lymph node procedure      203           68.4
   Axillary dissection                72            24.2
   NA                                 22            7.4
  Surgical revision                                 
   No                                 227           76.4
   1                                  60            20.2
   \>1                                10            3.4
  Type of hospitalisation                           
   Outpatient surgery                 107           36
   Conventional surgery               190           64
  **Adjuvant therapies**                            
  Radiotherapy                                      
   No                                 27            9.1
   Yes                                270           90.9
  Chemotherapy                                      
   Yes                                143           48.1
   No                                 154           51.9
  Trastuzumab                                       
   Yes                                36            12.1
   No                                 100           33.7
   NA                                 161           54.2
  Hormone therapy                                   
   Yes                                220           74.1
   No                                 77            25.9

Two hundred and twenty women (74.1%) underwent breast-conserving surgery and 77 (25.9%) underwent radical mastectomy ([table 1](#T1){ref-type="table"}). A sentinel lymph node procedure was performed for 203 patients (68.4%). Seventy patients required at least one reoperation for the following reasons: positive surgical margins and secondary mastectomy, sentinel lymph node procedure following discovery of an invasive tumour, axillary dissection following positive sentinel lymph node biopsy and surgical complications (abscess, haematoma and so on). After surgery, 90.9% of patients received radiotherapy 48.1% of patients received adjuvant chemotherapy and 74.1% of patients received hormone therapy.

Most patients were executives (31.4%) or employees (33.3%). Most patients (47.1%) had a monthly income \>€1900. Work data after BC were available for 178 patients (60%, online [supplemental figure 1](#SP1){ref-type="supplementary-material"}). Patients who did not complete ~~the 1~~work questionnaire in the logbook during 1 year were globally less compliant with the study and less medicalised (online [supplemental table 1](#SP2){ref-type="supplementary-material"}). Sick leave was prescribed for 165 patients (92.7%). Patients had only one sick leave in 52.2% of cases, two sick leaves in 21.9% of cases and three or more sick leaves in 18.5% of cases. Median duration of sick leave was 155 days (range: 5--365). After treatment, seven patients (3.9%) lost their jobs and 46.1% had reduced income. Patients encountered difficulties with their coworkers in 3.4% of cases, with their superiors in 3.9% of cases and for undocumented reasons in 12.9% of cases. Work-related factors are summarised in [table 2](#T2){ref-type="table"}.
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###### 

Work characteristics before and after BC

                                              n or Median   \% or Range
  ------------------------------------------- ------------- -------------
  **Work characteristics before BC, n=297**                 
  Type of occupation                                        
   Farmer                                     1             0.3
   Self-employed                              8             2.5
   Executive                                  99            31.4
   Employee                                   105           33.3
   Intermediate profession                    29            9.2
   Blue-collar worker                         2             0.6
   NA                                         53            22.9
  Personal income per month (€)                             
   No income                                  6             2
   \<1900                                     104           35
   \>1900                                     140           47.1
   NA                                         47            15.8
  **Work characteristics after BC, n=178**                  
  Dismissal                                   7             3.9
  Income change                                             
   Decreased                                  82            46.1
   Increased                                  3             1.7
   Stable                                     73            41
  NA                                          20            11.2
  Decreased income (%), n=82                                
   \<10                                       37            45.1
   10--30                                     13            15.8
   30--60                                     5             6.1
   \>60                                       3             3.7
   NA                                         24            29.3
  Sick leave                                                
   Yes                                        165           92.7
   No                                         13            7.3
  Number of sick leaves (n=165)                             
   1                                          93            52.2
   2                                          39            21.9
   \>2                                        33            18.5
  Duration of sick leave (days)               155           5--365
  Difficulties at work (n=36)                               
   With coworkers                             6             3.4
   With superiors                             7             3.9
   Other                                      23            12.9

BC, breast cancer.

On univariate analysis, the presence of clinical signs leading to a diagnosis of BC (p\<0.001), an invasive form of BC (p=0.02), lymph node involvement (p=0.005), radical surgery (p=0.02), axillary dissection (p\<0.001), chemotherapy (p\<0.001), personal income \<€1900/month (p=0.03) and not having received the work and cancer information booklet (p=0.047) were associated with a longer total duration of sick leave ([table 3](#T3){ref-type="table"}). Moreover, patients with longer sick leave were more likely to have reduced income after treatment of their disease (p=0.0012).

###### 

Determinants and consequences of long sick leave

                                        Sick leave \<155 days, n=79   Sick leave ≥155, days n=77   P values              
  ------------------------------------- ----------------------------- ---------------------------- ---------- ---------- -------------
  **Patient characteristics**                                                                                            
  Age (years)                           50.6                          27--59                       50         29--77     0.52
  Type of occupation                                                                                                     0.09
   Farmer                               0                             0                            0          0          
   Self-employed                        3                             3.8                          1          1.3        
   Executive                            36                            45.6                         29         37.7       
   Employee                             25                            31.6                         38         49.4       
   Intermediate profession              13                            16.5                         7          9.1        
   Blue-collar worker                   1                             1.3                          0          0          
   NA                                   1                             1.3                          2                     
  Personal income per month (€)                                                                               **0.03**   
   \<1900                               25                            31.6                         37         48.1       
   \>1900                               54                            68.4                         38         49.4       
   NA                                   0                             0                            2          2.6        
  Marital status                                                                                                         0.76
   Single                               18                            22.8                         12         15.6       
   Married                              47                            59.5                         49         63.6       
   Divorced                             12                            15.2                         14         18.2       
   Widow                                1                             1.3                          1          1.3        
   NA                                   1                             1.3                          1          1.3        
  **Breast cancer characteristics**                                                                                      
  Type of cancer                                                                                                         **\<0.001**
   Invasive                             63                            79.7                         74         96.1       
   In situ                              16                            20.3                         3          3.9        
  Lymph node involvement                                                                                                 **0.005**
   Yes                                  11                            13.9                         **26**     **33.8**   
   No                                   68                            86.1                         **52**     **67.5**   
  **Surgery**                                                                                                            
  Breast surgery                                                                                                         **0.02**
   Conservative                         66                            83.5                         50         64.9       
   Radical                              13                            16.5                         27         35.1       
  Lymph node surgery                                                                                                     **\<0.001**
   Sentinel lymph node procedure        62                            78.5                         48         62.3       
   Axillary dissection                  9                             11.4                         26         33.8       
   NA                                   8                             10.1                         3          3.9        
  Surgical revision                                                                                                      0.06
   Yes                                  13                            16.5                         23         29.9       
   No                                   66                            83.5                         54         70.1       
  Radiotherapy                                                                                                           0.53
   Yes                                  72                            91.1                         74         96.1       
   No                                   7                             8.9                          3          3.9        
  Chemotherapy                                                                                                           **\<0.001**
   Yes                                  25                            31.6                         56         72.7       
   No                                   54                            68.4                         21         27.3       
  Trastuzumab                                                                                                            0.54
   Yes                                  9                             11.4                         12         15.6       
   No                                   16                            20.3                         40         51.9       
   NA                                   54                            68.4                         25         32.5       
  Hormone therapy                                                                                                        0.05
   Yes                                  50                            63.3                         61         79.2       
   No                                   29                            36.7                         16         20.8       
  **Patient management**                                                                                                 
  Modes of diagnosis                                                                                                     **\<0.001**
   Organised screening                  15                            19                           21         27.3       
   Individual screening                 43                            54.4                         20         26         
   Clinical signs                       21                            26.6                         36         46.8       
  Type of hospitalisation                                                                                                **\<0.001**
   Outpatient surgery                   58                            73.4                         34         44.2       
   Inpatient surgery                    21                            26.6                         43         55.8       
  Work and cancer information booklet                                                                                    
   Yes                                  64                            81                           52         67.5       **0.047**
   No                                   15                            19                           25         32.5       
  **Return to work**                                                                                                     
  Dismissal 1                           1.3                           3                            3.9        0.62       
  Income change                                                                                                          
   Decreased                            23                            29.1                         48         62.3       **\<0.001**
   Increased                            0                             0                            2          2.6        
   Stable                               37                            46.8                         24         31.2       
   NA                                   19                            24.1                         3          3.9        
  Decreased income (%)                                                                                                   0.61
   \<10                                 11                            13.9                         21         27.3       
   10--30                               4                             5.1                          7          9.1        
   30--60                               0                             0                            4          5.2        
   \>60%                                0                             0                            3          3.9        
   NA                                   64                            81                           42         54.5       
  Difficulties at work                                                                                                   
   With coworkers                       2                             2.5                          3          3.9        0.67
   With superiors                       0                             0                            6          7.8        0.17
   Other                                7                             8.9                          14         18.2       0.93

Bold values means p\<0.05 (statistically significant).

On multivariate analysis, chemotherapy was the only independent factor associated with longer sick leave (OR: 3.5, 95% CI 1.6 to 7.9, p=0.002). Patients treated by chemotherapy had longer sick leave than those not treated by chemotherapy ([figure 1](#F1){ref-type="fig"}). The difference in terms of the 1-year distribution of sick leave was not statistically significant between patients according to whether or not they had received the work information booklet ([figure 2](#F2){ref-type="fig"}).

![Percentage of patients on sick leave at 1-year follow-up depending on the presence or absence of chemotherapy.](bmjopen-2017-020276f01){#F1}

![Percentage of patients on sick leave at 1-year follow-up depending on whether or not they had been given the work information booklet.](bmjopen-2017-020276f02){#F2}

Considering the working population of OPTISOINS01 study with complete data on sick leave and salary, the median cost of sick leave for National Health Insurance was €8841 per patient per year from diagnosis. On performing univariate and multivariate analyses, the only determinant of sick leave costs found in this study was the administration of chemotherapy, with a fourfold higher median allowance for patients treated with adjuvant chemotherapy.

Discussion {#s4}
==========

Although many BC cancer survivors are able to return to a normal work life after treatment, our study confirms that many women of working ages do not. Sick leave is frequently prescribed and is often long, with a median sick leave of 155 days in this study.

Factors associated with long sick leave (\>155 days) were severe or advanced forms of BC. The duration of sick leave was also associated with the mode of diagnosis, as patients diagnosed by breast screening presented shorter sick leaves. Public health authorities should therefore promote breast screening in order to decrease the proportion of advanced forms of BC and aggressive therapies with severe consequences on work and personal activities. Consequently, longer sick leave was also associated with more aggressive therapy, such as radical surgery, axillary dissection and chemotherapy. These results are similar to those published in the literature.[@R4] Chemotherapy is an aggressive treatment that can be necessary in order to improve survival, but which has long-lasting consequences in terms of self-esteem (alopaecia...), chronic pain (neuropathy...) and chronic fatigue, that play an important role in RTW and maintenance at work.[@R6] BC survivors may have to deal with the side effects specific to this type of treatment. Although many side effects of chemotherapy are only temporary,[@R14] some studies have shown that chemotherapy may impact on cognitive functioning[@R15] and fatigue[@R16] up to 10 years after diagnosis. Cognitive functioning and fatigue have both been associated with impaired work functioning.[@R17] Munir *et al* [@R18] reported that up to 62%--84% of women resumed work either during treatment with chemotherapy or following completion of treatment. As a result of their cognitive limitations, women reported that they experienced difficulties with their work ability, particularly difficulties doing multiple tasks, reduced clarity of decisions, deficits in clear thinking and feelings of being inept due to short-term memory.[@R19] Rapid progress is being made in the field of chemotherapy with the routine use of new genomic signature tests that allow more accurate targeting of patient likely to benefit from chemotherapy. According to Nesvold *et al* [@R20] and Eaker *et al* [@R14] mastectomy and axillary lymph node dissection may influence working life long after treatment due to an increased risk of chronic pain. BC survivors are more likely to suffer from upper extremity impairments or lymphoedema than are other cancer survivors,[@R21] which are responsible for difficulties at returning to work.[@R25]

The work and cancer information booklet appeared to help patients RTW with significantly shorter sick leave in univariate analysis, but not in the multivariate analysis. However, this suggests that an action, such as an active support, could help to reduce sick leave duration. The information booklet advises women to attend the occupational medicine service. In France, occupational medicine plays an essential role, but the patient is not obliged to consult the occupational physician when sick leave is \<3 months. However, at 3 months, the occupational physician and the employee must determine the modalities of RTW, based on the employee's state of health and the characteristics of the workplace. These arrangements concern the employee himself and the work collective with, if necessary, actions so that the reception is assured to the return. Setting up of a schedule, reduction of working hours, modification of physical, mental or workplace loads can also be instituted at the time of RTW. The occupational physician can provide recommendations to the employer, unless the employer refuses. The results obtained with this handbook are particularly encouraging and suggest that more individual supports should be developed. Health coaching by telephone and/or face-to-face interview have already been tested,[@R27] showing positive significant outcomes on physical activity, body mass index, pain management, acceptance of disease and self-confidence among cancer survivors. Coaching methods have never been tested in the management of working patients during cancer treatment~~maintenance~~. Our Institute is therefore setting up a prospective randomised study (OPTICOACH) with tailored support intervention to enhance RTW after BC in collaboration with a professional coach, consisting of individual interviews or small group workshops over a period of 3 years.

Difficulties at returning to work appear to extend over a period of many years. Sevellec *et al* [@R28] showed that 6 years after returning to work, one employee out of two was still working in the same company. Rather than disappearing, the difficulties identified many years after BC persist for a long time after stopping treatment. It is therefore essential to identify the factors associated with longer sick leave and RTW difficulties in order to help working patients and prevent these long-term problems. The VICAN 2 study[@R29] focused on the factors associated with difficulties at RTW. This large study was carried out in 2014 by the French National Cancer Institute, on the living conditions of people with cancer (not only BC), 2 years after the diagnosis. The people most vulnerable to job loss 2 years after the cancer diagnosis are mainly those working in the so-called socioprofessional execution categories, the youngest and oldest, married people with a level of education below the baccalaureate level and those with precarious contracts.

One of the potential biases of this study concerns the characteristics of the study population, as almost the majority of women belonged to the wealthiest social classes, as 45.6% of patients were executives and only 1.3% were blue-collar workers. More than 68% of patients had a personal monthly income \>€1900 and 36.7% had a personal monthly income \>€2600. This distribution does not exactly reflect French society; in France, according to the INSEE statistics of 2014, the median monthly income was €1772. Similarly to our results, a Canadian team[@R30] has shown that women with an annual income \<C\$20 000 were less likely to RTW than those whose income exceeded C\$50 000. The French social protection system also plays a role, as it provides cancer survivors with the possibility of replacement income, allowing women to decide whether or not they wish to RTW immediately. Providing assistance and support to all working patients should therefore be a priority.

Conclusion {#s5}
==========

Advanced disease and chemotherapy are major factors that influence RTW with longer sick leave. Systematic screening or use of innovative tools, such as genomic signatures, can facilitate earlier diagnosis and reduce aggressive therapies.

Depending on the type of treatment, stage of the disease and type of occupation, information and coaching methods with the occupational medicine service should systematically be given to working women, helping them to anticipate job adjustments with flexibility of work schedule for example.

Personalised coaching methods have been successfully used to promote acceptance of disease and self-confidence and should be tested in the management of RTW.
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